Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Neogen's price to sales ratio was 2.9× on Nov 11, 2026, against 1.5× a year earlier. Over the last 5 years it ranged from 1.1× to 10.0×, with a median of 3.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.9× | +1.2 |
| 2025 | Dec 31, 2025 | 1.7× | −1.2 |
| 2024 | Dec 31, 2024 | 2.9× | −1.8 |
| 2023 | Dec 29, 2023 | 4.7× | +1.6 |
| 2022 | Dec 30, 2022 | 3.1× | −6.9 |
| 2021 | Dec 31, 2021 | 10.0× | +0.1 |
| 2020 | Dec 31, 2020 | 9.9× | +1.6 |
| 2019 | Dec 31, 2019 | 8.2× | +0.9 |
| 2018 | Dec 31, 2018 | 7.3× | −1.1 |
| 2017 | Dec 29, 2017 | 8.4× | −1.6 |
| 2016 | Dec 30, 2016 | 10.1× | +0.4 |
| 2015 | Dec 31, 2015 | 9.7× | +0.2 |
| 2014 | Dec 31, 2014 | 9.5× | −0.7 |
| 2013 | Dec 31, 2013 | 10.2× | +2.6 |
| 2012 | Dec 31, 2012 | 7.6× | +2.2 |
| 2011 | Dec 30, 2011 | 5.4× | −3.5 |
| 2010 | Dec 31, 2010 | 9.0× | – |
See a number that looks wrong?